🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

RecruitingPhase 4Ages 18 Years - anyAllAsian Institute Of Medical Sciences
NCT07513168 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes mellitus. The study will be conducted at the Asian Institute of Medical Sciences (AIMS), Hyderabad, Sindh, Pakistan. A total of 60 obese adults aged 18 years or older with a body mass index (BMI) of 27.5 kg/m² or greater according to World Health Organization Asian cutoffs and without type 2 diabetes mellitus (fasting blood glucose \<126 mg/dL and HbA1c \<6.5%) will be enrolled. Eligible participants will receive once-weekly subcutaneous semaglutide following a standard dose titration schedule of 0.25 mg weekly for four weeks, 0.5 mg weekly for four weeks, and 1.0 mg weekly for the remaining 16 weeks, for a total treatment duration of 24 weeks. A

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years or older. * Body mass index (BMI ≥ 27.5 kg/m²) according to WHO Asian cut-offs. * No diagnosis of type 2 diabetes mellitus, confirmed by: Fasting blood glucose \< 126 mg/dL, and HbA1c \< 6.5% within three months prior to enrollment. * Willingness and ability to provide written informed consent. * Willingness to comply with study procedures, including weekly injections and lifestyle counseling. Exclusion Criteria: * History of pancreatitis. * History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). * Pregnant or lactating women. * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or hepatic impairment (ALT or AST \> 3× upper limit of normal). * Current use of other anti-obesity medications. * Known hypersensitivity to semaglutide or any component of the formulation. * Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.
💊

What it tests

  • Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
📍

Where

1 site
Asian Institute of Medical Sciences
Hyderābād, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy